Literature DB >> 19867226

FURTHER STUDIES ON IMMUNITY IN EXPERIMENTAL CRYPTOCOCCOSIS.

D B Louria1, T Kaminski, G Finkel.   

Abstract

Following infection with 10(3) cells of Cryptococcus neoformans, progressive multiplication occurred in all tissues for 7 to 28 days. Thereafter, most mice gained control of the infection so that 3 to 6 months after inoculation, tissues were usually sterile or contained only small numbers of cryptococci. Survivors challenged 1 to 4 months after infection with 10(3) cells lived longer than controls and had an increased survival rate. Pretreatment with bacterial endotoxin also resulted in protection against cryptococcal challenge. Endotoxin-protected animals showed no ability to limit the infection until circulating antibody could be demonstrated. Histologic studies revealed an increased cellular infiltration in the brains of specifically protected and endotoxin-protected mice 1 to 2 weeks after challenge. However, control of cryptococcal multiplication could be correlated with the presence of antibody but could not be correlated with the enhanced cellular response. Although protection against cryptococcal challenge appears to be antibody-dependent, it is unclear whether protective antibody is to be found in plasma or is tissue-bound.

Entities:  

Year:  1963        PMID: 19867226      PMCID: PMC2180444          DOI: 10.1084/jem.117.3.509

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Symposium on bacterial endotoxins. II. Possible mechanisms whereby endotoxins evoke increased nonspecific resistance to infection.

Authors:  J L WHITBY; J G MICHAEL; M W WOODS; M LANDY
Journal:  Bacteriol Rev       Date:  1961-12

2.  Fluorescent antibody techniques applied to the study of human cryptococcosis.

Authors:  R A VOGEL; T F SELLERS; P WOODWARD
Journal:  JAMA       Date:  1961-12-02       Impact factor: 56.272

3.  Studies on nonspecific acquired resistance to viral toxicity in mice.

Authors:  R M DOUGHERTY; V GROUPE
Journal:  Proc Soc Exp Biol Med       Date:  1957-07

4.  Active immunization against Cryptococcus neoformans.

Authors:  H H GADEBUSCH
Journal:  J Infect Dis       Date:  1958 May-Jun       Impact factor: 5.226

5.  Passive immunization against Cryptococcus neoformans.

Authors:  H H GADEBUSCH
Journal:  Proc Soc Exp Biol Med       Date:  1958-07

6.  Endotoxin in pathogenic q fungi.

Authors:  S B SALVIN
Journal:  J Immunol       Date:  1952-07       Impact factor: 5.422

7.  Functional and metabolic properties of polymorphonuclear leucocytes. II. The influence of a lipopolysaccharide endotoxin.

Authors:  Z A COHN; S I MORSE
Journal:  J Exp Med       Date:  1960-05-01       Impact factor: 14.307

8.  The effect of bacterial constituents on the resistance of mice to heterologous infection and on the activity of their reticulo-endothelial system.

Authors:  D BOEHME; R J DUBOS
Journal:  J Exp Med       Date:  1958-04-01       Impact factor: 14.307

9.  Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide.

Authors:  A G JOHNSON; S GAINES; M LANDY
Journal:  J Exp Med       Date:  1956-02-01       Impact factor: 14.307

10.  Specific and non-specific immunity in experimental cryptococcosis in mice.

Authors:  D B LOURIA
Journal:  J Exp Med       Date:  1960-05-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Immunity in cryptococcosis: an overview.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1982-03-19       Impact factor: 2.574

2.  Histopathological studies on experimental cryptococcosis in nude mice.

Authors:  K Nishimura; M Miyaji
Journal:  Mycopathologia       Date:  1979-09-28       Impact factor: 2.574

3.  The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.

Authors:  Antonio Nakouzi; Tong Zhang; Stefan Oscarson; Arturo Casadevall
Journal:  Vaccine       Date:  2009-04-19       Impact factor: 3.641

4.  Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts.

Authors:  Charles A Specht; Chrono K Lee; Haibin Huang; Donald J Tipper; Zu T Shen; Jennifer K Lodge; John Leszyk; Gary R Ostroff; Stuart M Levitz
Journal:  MBio       Date:  2015-12-22       Impact factor: 7.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.